- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04844307
Comparing Inpatient COVID-19 Outcomes in 2 Different PT Dosing Groups (CCPT)
Comparing COVID-19 Inpatient Outcomes When Treated With a Twice-a-day 15- Minute PT Program Versus a Once-a-day-30-minute PT Program
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
The 2019 pandemic struck New York City hospitals early and aggressively. In rehabilitating inpatients during the early part of the pandemic, we learned that many of them were too affected by the COVID-19 illness to be able to tolerate the typical 30-minute daily session of physical therapy. At that time, the physical therapy (PT) staff often accommodated patients by dividing the typical 30 minute daily session into two 15 minute sessions in an effort to increase patient tolerance and participation. However, it was discovered at that time that literature was scarce on whether these divided PT sessions were equal or superior to the typical sessions. Nor was there any substantial literature on whether shorter duration higher frequency sessions were better tolerated by the inpatient. The purpose of this prospective randomized non-blinded controlled study is to compare outcomes of COVID inpatients receiving one 30 minute daily session of PT to patients receiving two 15 minute daily sessions of PT.
In order to obtain high quality data on level of mobility during hospitalization, two separate scoring systems will be used: The AMPAC and JH-HLM scores. These two scoring systems have been selected for their wide acceptance in both the physiatry and physical therapy communities, and due to having confirmed inter-rater reliability and validity. These scores will be calculated by the physical therapist on initial evaluation, and then again on every session up until discharge. The physical therapy team at this community hospital have already received extensive education on the utilization of both of these scoring tools.
The rationale for this study is to determine whether shorter duration (15 minute) higher frequency sessions (2x a day) are better tolerated than the standard 30-minute session. We hypothesize that shorter duration higher frequency sessions are superior to standard inpatient PT sessions in terms of patient tolerance and change in mobility scores from admission to discharge. Supporting evidence is based on previous observation and from a recent survey given to 19 physical therapists actively working with COVID-19 inpatients at White plains Hospital: Healthier patients have a higher tolerance of the 30 minute sessions, and sicker patients have a poor tolerance of the 30 minute sessions.
Tipo di studio
Fase
- Non applicabile
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Ages 18-89.
- positive COVID19 status as confirmed by at least one positive nasopharyngeal/oropharyngeal swab or chest CT.
- PT referral placed and patient seen by PT within 72 hours of admission.
Exclusion Criteria:
- Patients who were deemed unable to actively participate in therapy due to poor cognitive status or being medically unstable.
- Patients who are unable to give consent.
- Patient who are bedbound at baseline.
- Patient who are not fluent in English or Spanish (a Spanish version of consent form will be made available)?
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Standard PT group
The standard PT group (control) will be receiving the standard 30 minute PT sessions 5 days a week.
There will be no variations from standard inpatient PT treatment except that subjects may receive more days of PT than patients who are not participating in study.
|
The standard PT session is 30 minutes once daily.
It routinely involves exercises designed to strengthen and increase mobility of the patient such as bed mobility, transfers, and ambulation.
In this study group there will be no variation from this standard treatment.
|
|
Sperimentale: Divided session PT group
The divided session PT group (experimental) will be receiving 15 minute sessions twice a day, five days a week.
The total number of minutes of PT time per day/week will be identical to the standard PT group, but divided into shorter and more frequent sessions.
|
The standard PT session (30 mins) will be divided into two 15 minute sessions spread out during the day.
Therefore, the total number of minutes of PT will not vary from the standard.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Patient tolerance
Lasso di tempo: Through completion of study, an average of 1 year
|
Patient tolerance will be recorded in minutes at end of each PT session in each group.
|
Through completion of study, an average of 1 year
|
|
Change in mobility scores from admission to discharge
Lasso di tempo: Through completion of study, an average of 1 year
|
Mobility scores including Activity Measure for Post Acute Care (AMPAC) and Johns Hopkins Highest Level of Mobility (JH-HLM) will be recorded at end of each PT session.
The change in scores from admission to discharge will be determined and recorded once patient is discharged.
|
Through completion of study, an average of 1 year
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Disposition
Lasso di tempo: Through completion of study, an average of 1 year
|
Disposition possibilities include home, home with services, acute rehab, subacute rehab or skilled nursing facility, LTACH, transfer to another acute care hospital, hospice/home with hospice, expired.
|
Through completion of study, an average of 1 year
|
|
Hospital Length of Stay
Lasso di tempo: Through completion of study, an average of 1 year
|
Total length of stay in the hospital will be determined based on date of admission and date of discharge from acute care hospital.
|
Through completion of study, an average of 1 year
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Anupama Kurra, MD, Montefiore Medical Center
Studiare le date dei record
Studia le date principali
Inizio studio (Anticipato)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Malattie cardiache
- Malattia cardiovascolare
- Malattie del sistema nervoso
- Infezioni da coronavirus
- Infezioni da Coronaviridae
- Infezioni da Nidovirus
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni delle vie respiratorie
- Malattie delle vie respiratorie
- Polmonite, virale
- Polmonite
- Malattie polmonari
- Manifestazioni neurologiche
- Malattie muscoloscheletriche
- Malattie muscolari
- Manifestazioni neuromuscolari
- Segni e sintomi, respiratori
- COVID-19
- Debolezza muscolare
- Fragilità
- Ipossia
- Cardiopatia polmonare
Altri numeri di identificazione dello studio
- 2021-12937
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su COVID-19
-
PfizerAttivo, non reclutanteCOVID-19 | Malattia da coronavirus 2019 (COVID-19) | Infezione da covid-19 | Vaccini contro il covid-19 | Infezione da SARS-CoV-2, COVID19 | Vaccinazione COVID-19 | Infezione da SARS-CoV-2, COVID-19 | COVID-19 (Coronavirus 2019) | Infezione da COVID-19 SARS-CoV-2Stati Uniti
-
Shanghai Public Health Clinical CenterNon ancora reclutamento
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Completato
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)ReclutamentoCondizione post COVID-19 | Post COVID-19 | Sindrome post COVID-19 | Sindrome lunga da COVID-19 | Condizione post COVID-19 (PCC)Germania
-
PfizerReclutamentoMalattie delle vie respiratorie | COVID-19 | Polmonite | Malattie polmonari | Malattia di coronavirus 2019 | Malattia da coronavirus 2019 (COVID-19) | Infezione da covid-19 | Infezioni del tratto respiratorio superiore | Infezione del tratto respiratorio | COVID-19 (Coronavirus 2019) | Infezione da COVID-19...Belgio
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaReclutamentoFatica | Sindrome post-COVID-19 | Condizione post COVID-19 | Sindrome post-COVID | Lungo COVID-19 | Lungo-COVID | Condizione post-COVIDCanada
-
RSUP PersahabatanCompletatoSindrome post COVID-19 | Sindrome lunga da COVID-19 | Sindrome Post COVID Long CovidIndonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNon ancora reclutamentoSindrome post-COVID-19 | Lungo COVID | Lungo Covid19 | Condizione post COVID-19 | Sindrome post-COVID | Condizione post COVID-19, non specificata | Condizione post-COVIDOlanda
-
ModeX Therapeutics, An OPKO Health CompanyReclutamentoCOVID 19 | COVID-19 (Prevenzione)Stati Uniti
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...CompletatoSequele post acute di COVID-19 | Condizione post COVID-19 | Lungo-COVID | Sindrome cronica da COVID-19Italia
Prove cliniche su Standard PT
-
NYU Langone HealthCompletatoArtroplastica totale articolareStati Uniti
-
Badr UniversityNon ancora reclutamento
-
Riphah International UniversityCompletatoSINDROME DELLA CROCE SUPERIOREPakistan
-
Riphah International UniversityCompletato
-
Vanderbilt University Medical CenterUnited States Department of DefenseReclutamentoDegenerazione della colonna vertebrale cervicale | Chirurgia ACDFStati Uniti
-
Promontory Therapeutics Inc.Attivo, non reclutanteNeoplasie urogenitali | Neoplasie per sede | Neoplasie genitali, maschio | Neoplasie prostatiche | Tumori solidi avanzati | mCRPC | Cancro alla prostata metastatico resistente alla castrazione | CRP | PT-112Stati Uniti, Francia
-
Riphah International UniversityCompletatoDolore al collo non specificoPakistan
-
Brooke Army Medical CenterReclutamentoDisturbi temporomandibolari (TMD)Stati Uniti
-
Medical University of South CarolinaCompletatoIctus | Ictus, ischemico | Ictus, AcutoStati Uniti
-
DBV TechnologiesUniversity Hospital, GenevaCompletato